Form 8-K Autolus Therapeutics For: May 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Wells Fargo Reiterates Overweight Rating on Autolus Therapeutics plc (AUTL)
May 20, 2024 6:43 AM EDTWells Fargo analyst Yanan Zhu reiterated an Overweight rating and $8.00 price target on Autolus Therapeutics plc (NASDAQ: AUTL).
The analyst comments "We continue to see AUTL as well positioned for upside on 2H24 catalysts incl. B-ALL PDUFA (11/16) and first SLE data (late... More
